To access this element change to forms mode OFF
Grant Award View - GA22056
Prodrug Development of Biased N-Alkylpyridazinones for the Acute...
GA ID:
GA22056
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
16-Jul-2018
Publish Date:
19-Sep-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2020
Value (AUD):
$677,127.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Prodrug Development of Biased N-Alkylpyridazinones for the Acute Intravenous Treatment of Myocardial Ischaemia-Reperfusion Injury
Purpose:
The leading cause of death worldwide, accounting for 30 percent of all global deaths, is cardiovascular disease. This figure has heart attack and associated changes heart oxygen levels as a major injury-causing component. We have discovered a potential treatment that is limited by its solubility properties. In this RandD plan we will develop soluble preclinical progression drug candidates for the treatment of oxygen-related heart attack injury.
GO ID:
GO Title:
Development Grants
Internal Reference ID:
GNT1155527
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC
Postcode:
Multiple
Country:
AUSTRALIA